Cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation / Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp.

Format:

Book

Author/Creator:

Hagen, Gunhild, author.

Wisløff, Torbjørn, author.

Klemp, Marianne, author.

Series:

Rapport fra Kunnskapssenteret, nr. 10-2010, no. 10-2010 ; nr 206

Language:

English

Subjects (All):

Smoking cessation.

Cost effectiveness.

Physical Description:

1 online resource (1 PDF file (48 pages)) : illustrations.

Place of Publication:

Oslo : Norwegian Knowledge Centre for the Health Services, 2010.

Summary:

Background Smoking is an important risk factor for several diseases, including different cancers, lung diseases and cardiovascular diseases. About 21% of the Norwegian population are daily smokers. Interventions for smoking cessation are normally divided into counselling and drug treatment support. In Norway, two prescription drugs are available for use in smoking cessation; varenicline (Champix (r) or Chantix (r)) and bupropion (Zyban (r)). In addition, several options for nicotine replacement therapy are available, such as nicotine-gum, patches and lozenges. Commission We were commissioned to evaluate the cost-effectiveness of drugs for smoking cessation in a Norwegian setting. The economic evaluation will inform the revised treatment guideline for smoking cessation in primary care. Main findings1. Compared to no treatment, nicotine replacement therapy, bupropion and varenicline can all be considered cost-effective.2. When the drugs are evaluated relative to each other, varenicline is the most cost-effective alternative.

Notes:

Description based on publisher supplied metadata and other sources.